Biodesix (BDSX) chair converts 1,361 RSUs and updates holdings
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Biodesix Inc. director and chairman John Patience reported a routine equity compensation transaction involving restricted stock units (RSUs) that converted into common shares. On June 30, 2026, he exercised 1,361 RSUs, receiving 1,361 shares of common stock, increasing his direct common stock holdings to 25,383 shares.
Following the transaction, he also directly holds 2,721 RSUs, each representing a contingent right to one share of common stock. These RSUs vest in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to his continued service with Biodesix. The filing also lists indirect holdings of common stock held by his spouse, the John Patience Living Trust dated July 23, 1993, and Patience Enterprises LP.
Positive
- None.
Negative
- None.
Insider Trade Summary
1,361 shares exercised/converted
Mixed
5 txns
Insider
PATIENCE JOHN
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 1,361 | $0.00 | -- |
| Exercise | Common Stock | 1,361 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 2,721 shares (Direct, null);
Common Stock — 25,383 shares (Direct, null);
Common Stock — 107,664 shares (Indirect, By Patience Enterprises LP)
Footnotes (1)
- Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock"). The Reporting Person is the sole general partner of Patience Enterprises LP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. The Reporting Person is the sole trustee of John Patience Living Trust (July 23, 1993). These RSUs vest in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.
Key Figures
RSUs exercised: 1,361 units
Direct common shares after transaction: 25,383 shares
RSUs outstanding after transaction: 2,721 units
+3 more
6 metrics
RSUs exercised
1,361 units
Converted into common stock on June 30, 2026
Direct common shares after transaction
25,383 shares
Common stock held directly following RSU conversion
RSUs outstanding after transaction
2,721 units
Restricted stock units remaining after June 30, 2026
Indirect shares by spouse
2,649 shares
Common stock held indirectly through spouse
Indirect shares via living trust
241,480 shares
Common stock held by John Patience Living Trust dated July 23, 1993
Indirect shares via Patience Enterprises LP
107,664 shares
Common stock held by Patience Enterprises LP
Key Terms
Restricted Stock Units, pecuniary interest, beneficial ownership, Section 16, +1 more
5 terms
Restricted Stock Units financial
"Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
pecuniary interest financial
"The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein"
beneficial ownership financial
"shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Section 16 regulatory
"for purposes of Section 16 or for any other purpose"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
vesting financial
"These RSUs vest in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What did Biodesix (BDSX) director John Patience report in this Form 4?
He reported a routine equity compensation event where 1,361 restricted stock units converted into 1,361 shares of Biodesix common stock, increasing his direct common holdings to 25,383 shares as of June 30, 2026, with no open‑market buying or selling disclosed.
What is the vesting schedule for John Patience’s 2026 Biodesix RSUs?
These restricted stock units vest in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026. Vesting generally requires his continued service with Biodesix, meaning units convert into shares over the year as each vesting date is reached.
Does this Biodesix (BDSX) Form 4 show any open‑market stock purchases or sales?
No open‑market purchases or sales are shown. The primary report is an exercise of 1,361 restricted stock units into common stock, a non‑cash equity compensation event. Additional lines update indirect holdings through his spouse, a living trust, and Patience Enterprises LP.
What indirect Biodesix holdings are associated with John Patience in this Form 4?
The filing lists indirect common stock holdings of 2,649 shares held by his spouse, 241,480 shares held by the John Patience Living Trust dated July 23, 1993, and 107,664 shares held by Patience Enterprises LP, where he is the sole general partner with a disclosed pecuniary interest.
How many restricted stock units does John Patience hold after the June 30, 2026 transaction?
He holds 2,721 restricted stock units after the transaction. Each RSU represents a contingent right to receive one share of Biodesix common stock, with vesting occurring in four substantially equal installments across specific dates in 2026, subject to continued service conditions.